An ultrasound test that detected 96% of ovarian cancers in postmenopausal women should replace the current standard of care test in the UK according to a new study. In a paper published in The Lancet Oncology today, research led by Professor Sudha Sundar from the University of Birmingham compared all currently available tests to diagnose ovarian cancer in postmenopausal women head-to-head in a high-quality diagnostic test accuracy study. Of the six diagnostic tests investigated, the IOTA ADNEX model which looks at ultrasound features (how the lump looked like on ultrasound) had the best accuracy of all and could detect up to 96% of women with ovarian cancer.
The ultrasound test outperforms the current standard of care in the UK significantly and so we recommend that the IOTA ultrasound ADNEX model should replace the current standard of care test called risk of malignancy (RMI1) test in the UK, which identifies 83% of ovarian cancers . Sudha Sundar, Professor of Gynecological Cancer at the University of Birmingham and consultant in gynecological cancer surgery at Sandwell and West Birmingham NHS Trust said, "This is the first time that a head-to-head study of all available ovarian cancer tests has been done in the same population. Here we studied their use with symptomatic, postmenopausal women who are most at risk of this cancer.
Our trial found that the IOTA ADNEX ultrasound protocol had the highest sensitivity for detecting ovarian cancer compared to the standard of care an.